MedTrace Logo

Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer

NCT01700400 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-11-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether the investigational study drug everolimus may be used to increase the effectiveness of chemotherapy treatment for patients with advanced lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Everolimus

DRUG

Pemetrexed

DRUG

Carboplatin

DRUG

Bevacizumab

Sponsors & Collaborators

  • University of Arizona

    collaborator OTHER

  • Providence Cancer Center, Earle A. Chiles Research Institute

    collaborator OTHER

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Cancer Research and Biostatistics Clinical Trials Consortium

    lead NETWORK

Principal Investigators

  • Linda L. Garland, MD · University of Arizona

  • John Crowley, PhD · Cancer Research And Bioststistics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01700400 on ClinicalTrials.gov